VALE S.A. (VALE) Spending and interest coverage
- R&D / revenue · 12 months: Value 3.03%; Formula and calculation Research and development expense / revenue. Period ending 2012-12-31..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2012-12-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2012-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 3.03% | Research and development expense / revenue. Period ending 2012-12-31. $1.48B ÷ $48.75B × 100 ≈ 3.03% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2012-12-31. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.48B USD | Research and Development Expense |
| Revenue | 48.75B USD | |
| Stock-based compensation | (m) | |
| Operating income | 9.22B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2012-12-31 | $1.48B | $48.75B | (m) | $9.22B | (m) | 3.03% | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $1.63B | $58.18B | (m) | $25.99B | (m) | 2.80% | (m) | (m) | (m) |
| 2011-12-31 | $1.67B | $60.39B | (m) | $30.11B | (m) | 2.77% | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $1.05B | $53.18B | (m) | $27.60B | (m) | 1.97% | (m) | (m) | (m) |
| 2010-12-31 | $878.00M | $46.48B | (m) | $21.70B | (m) | 1.89% | (m) | (m) | (m) |
| 2010-09-30 | $873.00M | $37.81B | (m) | $15.63B | (m) | 2.31% | (m) | (m) | (m) |
| 2010-06-30 | $888.00M | $30.21B | (m) | $10.09B | (m) | 2.94% | (m) | (m) | (m) |
| 2010-03-31 | $964.00M | $25.37B | (m) | $6.43B | (m) | 3.80% | (m) | (m) | (m) |
| 2009-12-31 | $981.00M | $23.94B | (m) | $6.06B | (m) | 4.10% | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $1.08B | $38.51B | (m) | $14.75B | (m) | 2.82% | (m) | (m) | (m) |
| 2007-12-31 | $733.00M | $33.12B | (m) | $13.19B | (m) | 2.21% | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.